Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvi Japan Oppo. Regulatory News (AJOT)

Share Price Information for Avi Japan Oppo. (AJOT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 131.00
Bid: 129.50
Ask: 132.50
Change: 2.00 (1.55%)
Spread: 3.00 (2.317%)
Open: 131.00
High: 131.00
Low: 129.50
Prev. Close: 129.00
AJOT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Quarterly Newsletter

13 Jan 2020 17:18

RNS Number : 6581Z
AVI Japan Opportunity Trust PLC
13 January 2020
 

13 January 2020

 

AVI JAPAN OPPORTUNITY TRUST PLC

 

(the "Company")

 

 

Quarterly Newsletter

The Company presents its Quarterly Newsletter, reporting operating performance, corporate governance developments and the progress of the Company's engagements for the period ending 31 December 2019.

This Quarterly Newsletter is available on the Company's website at:

https://www.ajot.co.uk/content/uploads/2020/01/Q4-2019-AJOT-Quarterly-Letter.pdf

Portfolio Statistics

 

Net cash1 as

percentage of

market cap

 

 

NFV2 as a

percentage of

Market cap

 

 

EV/EBIT

FCF Yield

EV FCF Yield3

Dividend Yield

 

45%

 

 

81%

 

3.8

 

5.8%

 

22.3%

 

2.0%

 

Dear AJOT Shareholders,

 

This quarter's strong performance, with a NAV return of +9.5% vs the MSCI Small Cap Japan's +0.6%, was particularly pleasing after we added to positions which suffered from weakness over the summer. Six of the top ten contributors this quarter were amongst the largest detractors last quarter. Toshiba Plant, for example, was this quarter's largest contributor with a share price increase of +48% following a fall of -10% last quarter, and Teikoku Sen-i was the third largest contributor this quarter (+34%; -15% as the largest detractor previously). While only a small sample size, this highlights the benefits of taking advantage of short-term price declines which increase the discrepancies between fundamental value and the market value of our investments.

 

While a good period, there are plenty of situations in our portfolio where we still see major divergences between value and market price. We have been opportunistically adding to these situations, as well as starting to build two new positions with the proceeds from divesting NuFlare and Toshiba Plant.

 

The New Toshiba and AJOT's Subsidiary Investments

 

Approximately half of this quarter's performance was driven by Toshiba Plant Systems & Services and NuFlare Technology, which added +2.5% and +2.3% respectively to returns. Both Toshiba Plant and NuFlare received bids from their parent company, Toshiba Corp, at premiums of +28% and +46% to their prevailing share prices. We exited the positions in both companies following the offer, crystallising strong IRRs of +110% for NuFlare and +35% for Toshiba Plant (in local currency).

 

Toshiba Corp's offer is a vindication of the "parent-child" theme within AJOT's portfolio. We wrote about this extensively in our Q3 2019 letter, arguing that listed subsidiaries should be either bought in or sold off by the parent company given that the potential for the abuse of minority shareholders' rights depresses share prices. With the Abe administration having been critical of these sorts of arrangements, and Toshiba Corp's recently refreshed Board, it felt like simply a matter of time before the company would acquire or sell off its stakes in NuFlare and Toshiba Plant. After AJOT's exit from NuFlare and Toshiba Plant, there remain three companies, exposed to the parent-subsidiary theme in the portfolio, accounting for 10% of NAV.

 

The actions of Toshiba Corp add to the weight of evidence that AJOT's overarching thesis is valid. With pressure coming from the government, and increasingly shareholder-conscious institutional investors, Japan Inc. is shifting - slowly, but surely - towards a more efficient, fairer system of governance. The Toshiba Corp offer is but one example of this; we see further evidence in the form of rising share buybacks; higher payout ratios; increasing returns on equity; reductions in cross-shareholdings; and increasingly independent boards. We believe that our portfolio of high-quality, cash-generative, undemandingly-valued companies stands to benefit from this trend.

 

1 Net cash = Cash - Debt - Net Pension Liabilities 

2 Net Financial Value (NFV) = Net cash + Investment Securities

3 The effective free cash flow yield were non-core assets to be distributed

 

 

Fujitec - Going Up

 

Fujitec is a global elevator manufacturer, selling to customers in Japan, China, Southeast Asia, North America and Europe. With a 5.5% weight in the portfolio, it is our fourth largest position and since launch has been the third biggest contributor. The strong performance (+29% on our average buy-in price) has been driven by a slight increase in Fujitec's valuation but owes more to improved operating performance, with profit growth for the first half of the year of +50% and forecast full year growth of +15%.

 

The most appealing aspect of Fujitec's business is the maintenance contracts that it receives after the installation of an elevator. These last for decades, producing steady, recurring profit. This is not lost on the market with Fujitec's global peers trading on EV/EBIT multiples of 20x, and the emerging bidding war for thyssenkrupp's elevator business - with some of the world's largest private equity managers vying for a stake - highlighting the attraction of the business model.

 

However, Fujitec, exposed to the same industry dynamics, trades on an EV/EBIT multiple of just 8x. We attribute Fujitec's lower valuation to several factors. 1) Poor balance sheet efficiency. One third of Fujitec's balance sheet is allocated to low yielding cash and investment securities, which accounts for 46% of Fujitec's market cap. These contribute little to profits and are valued at a heavy discount by the market. 2) Poison pill. Fujitec first introduced a poison pill in 2007 to fend off a proposed buyout. By restricting potential buyers, it removes the possibility of a takeover, thus leading to a valuation discount. 3) Weaker margins. Fujitec suffers from lower operating margins than peers, 7% vs 12%, driven by lesser scale and an overly diversified exposure to non-core geographies. 4) Lack of sell-side coverage. No sell-side analysts cover Fujitec while Kone and Schindler are covered by 30 and 21 analysts, respectively.

 

We are working with management and the Board to address these problems, and they have so far been receptive to our suggestions. Considering not only the valuation but also margin upside, we believe the share price could double over the medium-term. Fujitec represents one of the most compelling investments in AJOT's portfolio.

 

***

 

Our most recent trip to Japan was accompanied by articles from the Nikkei and Bloomberg. They reported that we were considering making proposals to six Japanese companies over the coming year. While we are unable to comment on the progress we have made, or which companies we plan to target, it should be noted that we are ramping up our engagement. We hope that our discussions can stay behind closed doors away from the public spotlight, but the management of our companies know that should progress not be forthcoming, we have the ability and willingness to take our views public.

 

Share Issuance

Over the coming months we plan to raise additional funds via share issuances. There is growing evidence in Japan that companies are taking corporate governance more seriously and responding to shareholder engagement. We continue to find attractive opportunities both in our existing holdings and new investments.

Please do get in touch if you have any questions.

 

- ENDS -

 

For further information please contact:

Joe Bauernfreund, Asset Value Investors

Tel: 020 7659 4800

info@ajot.co.uk 

 

Fiona Harris, Quill PR

Tel: 020 7466 5058 / 07792 523455

fiona@quillpr.com

 

Sarah Gibbons-Cook

Tel: 020 7466 5060/ 07769 648806

sarah@quillpr.com 

 

Andreea Caraveteanu, Quill PR

Tel: 020 7466 5059 / 07902 142991

andreea@quillpr.com 

 

The content of the Company's web-pages and the content of any website or pages which may be accessed through hyperlinks on the Company's web-pages, other than the content of the Update referred to above, is neither incorporated into nor forms part of the above announcement.

LEI: 894500IJ5QQD7FPT3J73

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DOCUOABRRRUAAAR
Date   Source Headline
3rd May 202412:59 pmRNSNet Asset Value(s)
2nd May 202412:20 pmRNSNet Asset Value(s)
1st May 20242:49 pmRNSResult of AGM
1st May 202412:52 pmRNSNet Asset Value(s)
30th Apr 202412:35 pmRNSNet Asset Value(s)
29th Apr 20241:15 pmRNSNet Asset Value(s)
26th Apr 20243:02 pmRNSNet Asset Value(s)
25th Apr 20243:34 pmRNSNet Asset Value(s)
24th Apr 202412:40 pmRNSNet Asset Value(s)
23rd Apr 202412:25 pmRNSNet Asset Value(s)
22nd Apr 20241:04 pmRNSNet Asset Value(s)
19th Apr 202412:32 pmRNSNet Asset Value(s)
18th Apr 202412:45 pmRNSNet Asset Value(s)
17th Apr 20243:05 pmRNSNet Asset Value(s)
16th Apr 202412:29 pmRNSNet Asset Value(s)
15th Apr 20241:18 pmRNSNet Asset Value(s)
12th Apr 20245:33 pmRNSQuarterly Newsletter
12th Apr 20245:03 pmRNSMonthly Update
12th Apr 202410:49 amRNSNet Asset Value(s)
11th Apr 202411:51 amRNSNet Asset Value(s)
10th Apr 202412:53 pmRNSNet Asset Value(s)
9th Apr 202412:18 pmRNSNet Asset Value(s)
8th Apr 202412:20 pmRNSNet Asset Value(s)
5th Apr 202412:56 pmRNSNet Asset Value(s)
4th Apr 20241:01 pmRNSNet Asset Value(s)
3rd Apr 202412:54 pmRNSNet Asset Value(s)
2nd Apr 20243:28 pmRNSNet Asset Value(s)
2nd Apr 202411:03 amRNSTotal Voting Rights
28th Mar 202411:55 amRNSNet Asset Value(s)
27th Mar 20242:58 pmRNSNet Asset Value(s)
26th Mar 20243:49 pmRNSDirector/PDMR Shareholding
26th Mar 202412:56 pmRNSNet Asset Value(s)
25th Mar 20243:16 pmRNSNet Asset Value(s)
22nd Mar 202412:57 pmRNSNet Asset Value(s)
21st Mar 202411:07 amRNSNet Asset Value(s)
20th Mar 202412:13 pmRNSNet Asset Value(s)
19th Mar 20245:34 pmRNSMonthly update
19th Mar 20242:39 pmRNSNet Asset Value(s)
18th Mar 20242:23 pmRNSNet Asset Value(s)
15th Mar 20245:29 pmRNSTransaction in Own Shares
15th Mar 20241:29 pmRNSNet Asset Value(s)
15th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 20241:49 pmRNSInvestment Manager Increases Holding
14th Mar 20241:19 pmRNSNet Asset Value(s)
14th Mar 20247:00 amRNSAnnual Financial Report
13th Mar 202412:31 pmRNSNet Asset Value(s)
12th Mar 202412:34 pmRNSNet Asset Value(s)
11th Mar 202412:52 pmRNSNet Asset Value(s)
8th Mar 202412:37 pmRNSNet Asset Value(s)
7th Mar 20241:00 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.